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Abstract: BACKGROUND: Transcatheter aortic valve replacement (TAVR) is being increasingly per-
formed in patients with bicuspid aortic valve stenosis (AS). OBJECTIVES: This study sought to compare
the procedural and clinical outcomes in patients with bicuspid versus tricuspid AS from the Bicuspid AS
TAVR multicenter registry. METHODS: Outcomes of 561 patients with bicuspid AS and 4,546 patients
with tricuspid AS were compared after propensity score matching, assembling 546 pairs of patients with
similar baseline characteristics. Procedural and clinical outcomes were recorded according to Valve Aca-
demic Research Consortium-2 criteria. RESULTS: Compared with patients with tricuspid AS, patients
with bicuspid AS had more frequent conversion to surgery (2.0% vs. 0.2%; p = 0.006) and a signifi-
cantly lower device success rate (85.3% vs. 91.4%; p = 0.002). Early-generation devices were implanted
in 320 patients with bicuspid and 321 patients with tricuspid AS, whereas new-generation devices were
implanted in 226 and 225 patients with bicuspid and tricuspid AS, respectively. Within the group re-
ceiving early-generation devices, bicuspid AS had more frequent aortic root injury (4.5% vs. 0.0%; p
= 0.015) when receiving the balloon-expanding device, and moderate-to-severe paravalvular leak (19.4%
vs. 10.5%; p = 0.02) when receiving the self-expanding device. Among patients with new-generation
devices, however, procedural results were comparable across different prostheses. The cumulative all-
cause mortality rates at 2 years were comparable between bicuspid and tricuspid AS (17.2% vs. 19.4%;
p = 0.28). CONCLUSIONS: Compared with tricuspid AS, TAVR in bicuspid AS was associated with a
similar prognosis, but lower device success rate. Procedural differences were observed in patients treated
with the early-generation devices, whereas no differences were observed with the new-generation devices.
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ABSTRACT
BACKGROUND Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with
bicuspid aortic valve stenosis (AS).
OBJECTIVES This study sought to compare the procedural and clinical outcomes in patients with bicuspid versus
tricuspid AS from the Bicuspid AS TAVR multicenter registry.
METHODS Outcomes of 561 patients with bicuspid AS and 4,546 patients with tricuspid AS were compared after
propensity score matching, assembling 546 pairs of patients with similar baseline characteristics. Procedural and clinical
outcomes were recorded according to Valve Academic Research Consortium-2 criteria.
RESULTS Compared with patients with tricuspid AS, patients with bicuspid AS had more frequent conversion to surgery
(2.0% vs. 0.2%; p ¼ 0.006) and a signiﬁcantly lower device success rate (85.3% vs. 91.4%; p ¼ 0.002). Early-generation
devices were implanted in 320 patients with bicuspid and 321 patients with tricuspid AS, whereas new-generation devices
were implanted in 226 and 225 patients with bicuspid and tricuspid AS, respectively. Within the group receiving
early-generation devices, bicuspid AS had more frequent aortic root injury (4.5% vs. 0.0%; p ¼ 0.015) when receiving the
balloon-expanding device, and moderate-to-severe paravalvular leak (19.4% vs. 10.5%; p ¼ 0.02) when receiving the
self-expanding device. Among patients with new-generation devices, however, procedural results were comparable across
different prostheses. The cumulative all-cause mortality rates at 2 years were comparable between bicuspid and tricuspid
AS (17.2% vs. 19.4%; p ¼ 0.28).
CONCLUSIONS Compared with tricuspid AS, TAVR in bicuspid AS was associated with a similar prognosis, but lower
device success rate. Procedural differences were observed in patients treated with the early-generation devices,
whereas no differences were observedwith the new-generation devices. (J AmColl Cardiol 2017;69:2579–89)© 2017 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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T ranscatheter aortic valve replace-ment (TAVR) has evolved from anovel technology to an established
therapy for high-risk patients with symptom-
atic severe aortic valve stenosis (AS).
Numerous studies have demonstrated the
safety and efﬁcacy of TAVR, and more than
250,000 patients have been treated with
this technology (1–6). Although randomized trials
have established TAVR as the standard treatment in
inoperable patients and a reasonable option in high
surgical-risk patients, these trials excluded congen-
ital bicuspid AS due to its unique morphological
features (1,2,5–7).
The experience of TAVR in bicuspid AS is limited to
small series (8–12). Based on data from previous reg-
istries, the proportion of patients with bicuspid AS
may reach 2% to 6% (13,14). Previous studies were
limited by the clear baseline differences in age and
comorbidities favoring the bicuspid AS study group
SEE PAGE 2590
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CI = conﬁdence interval
OR = odds ratio
TAVR = transcatheter aortic
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compared with the tricuspid AS study group. How-
ever, there is a paucity of data comparing the clinical
outcomes of TAVR in bicuspid and tricuspid AS. Given
the increasing frequency of bicuspid AS in younger
patients, coupled with the worldwide shift toward
treating younger and lower surgical-risk patients with
TAVR, the clinical outcomes of TAVR in bicuspid AS
warrant special attention (6,15,16). Furthermore,
current TAVR practice is largely based on evidence on
TAVR for tricuspid AS, and thus, understanding the
differences in clinical outcomes of TAVR in bicuspid
and tricuspid AS is meaningful. Therefore, we aim to
evaluate the clinical outcomes of TAVR in bicuspid AS
and compare them to tricuspid AS. In addition, the
differences in outcomes between bicuspid versus
tricuspid AS will be analyzed, taking into consider-
ation the technological developments in trans-
catheter valves.
METHODS
STUDY DESIGN AND PATIENT POPULATION. The
Bicuspid AS TAVR registry is an international, multi-
center, observational study that enrolled all consec-
utive patients with bicuspid AS undergoing TAVR.
The registry was initiated in December 2013, and a
total of 33 centers from Europe, North America, and
the Asia-Paciﬁc region contributed to the registry. We
collected data retrospectively for cases performed
before initiation, and prospectively thereafter. All
inconsistencies were resolved directly with local
investigators and on-site data monitoring. For the
purpose of this study, data for all consecutive
patients with tricuspid AS treated with TAVR during
the same period were collected from 12 participating
centers, and procedural and clinical outcomes of pa-
tients with bicuspid and tricuspid AS were compared.
As a secondary analysis, the outcomes of TAVR in
bicuspid AS were compared with those with tricuspid
AS according to device type. This study was approved
by the institutional review board of each institution,
and all patients provided written informed consent
for TAVR and the use of anonymous clinical, proce-
dural, and follow-up data for research. For a retro-
spective analysis of clinically acquired and
anonymized data, the institutional review boards of
some institutions waived the need for written patient
informed consent.
BICUSPID AORTIC VALVE. Bicuspid aortic valve
morphology was classiﬁed as previously described
by Sievers and Schmidtke (15) according to the
number of cusps and the presence of raphes, as well
as spatial position and symmetry of raphes and
cusps. Type 0 was assigned to morphologies
characterized by the presence of 2 symmetric cusps
and 1 commissure without evidence of a raphe. Type
1 was assigned to valve morphologies with 1 raphe,
and type 2 when 2 raphes were present. All partici-
pating centers reviewed and subsequently conﬁrmed
the diagnosis and classiﬁcation of bicuspid AS. When
both transesophageal echocardiography and pre-
procedural computed tomography were performed,
patients were excluded if the diagnosis of bicuspid
aortic valve was not consistent or remained
speculative.
STUDY DEVICES AND PROCEDURE. Patients were
selected for TAVR at the institutional level after
discussions by the multidisciplinary heart team. The
access site was determined by the multidisciplinary
heart team. All centers adopted a transfemoral-ﬁrst
approach policy, with criteria for performing a non-
transfemoral approach based on the heart team’s
consideration of the size, calciﬁcation, and atheroma
of the aorto-iliofemoral artery. Device sizes were
selected based on 3-dimensional, multidetector-row
computed tomography–based annular measurements
or transesophageal echocardiogram assessment. All
TAVR procedures were conducted in accordance with
local guidelines using standard techniques via trans-
femoral, transapical, trans-subclavian, or transaortic
access, and the early-generation devices (the Sapien
XT [Edwards Lifesciences, Irvine, California] and
CoreValve [Medtronic, Minneapolis, Minnesota]) or
new-generation devices (the Sapien 3 [Edwards
Lifesciences], Lotus [Boston Scientiﬁc, Natick,
Massachusetts] and Evolut R [Medtronic]) were
implanted (17–22).
ENDPOINTS AND DEFINITIONS. The primary endpoint of
the present study was all-cause mortality at 1 and
2 years. Secondary endpoints were 30-day major clin-
ical endpoints using the Valve Academic Research
Consortium (VARC)-2 criteria (23). Device success was
deﬁned as a composite endpoint including: 1) absence
of procedure-related death; 2) correct positioning
of a single prosthetic heart valve into the proper
anatomic location; and 3) intended performance of
the prosthetic heart valve (no prosthesis–patient
mismatch, mean aortic gradient <20 mm Hg or
peak velocity <3 m/s, and no moderate or severe
paravalvular leak). Other endpoints included new
permanent pacemaker insertion, procedure- and
device-related complications, and echocardiographic
assessment of the valve and cardiac function at
discharge. No echocardiographic core laboratory
was used, and all echocardiographic data were
site-reported. The severity of regurgitation was
qualitatively assessed and graded using
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transthoracic echocardiography at each institution,
according to established guidelines (23).
DATA COLLECTION. Data collection by a dedicated
case report form included baseline clinical, labora-
tory, echocardiographic, and computed tomographic
data, as well as procedural data and clinical follow-up
data at pre-speciﬁed time points (1, 6, and 12 months,
and yearly thereafter). Follow-up was obtained by
clinical visits and/or through telephone contacts.
Referring cardiologists, general practitioners, and
patients were contacted whenever necessary for
further information. All data provided by each insti-
tution were anonymized, centrally collected, and
assessed for quality.
STATISTICAL ANALYSIS. Given the differences in
baseline clinical, echocardiographic, and procedural
characteristics between patients with bicuspid and
tricuspid AS, propensity score matching was applied
to identify a cohort of patients with similar baseline
characteristics, and thus, clinical outcomes of pro-
pensity score–matched cohorts were compared. The
propensity score is a conditional probability of having
a particular exposure (bicuspid AS or tricuspid AS),
given a set of covariates measured at baseline. The
propensity score has been developed using a logistic
regression model according to a nonparsimonious
approach, and all clinical variables (age, sex,
New York Heart Association functional class III or IV,
hypertension, diabetes mellitus, creatinine, periph-
eral vascular disease, prior cerebrovascular accident,
chronic lung disease, prior percutaneous coronary
intervention, prior coronary artery bypass graft, mean
gradient, and left ventricular ejection fraction) as well
as procedural data (transfemoral access and device
type were included in the analysis. Additionally, we
created propensity score–matched cohorts for sub-
groups (early- and new-generation devices), and
outcomes were compared. The details of the pro-
pensity score method are described in the Online
Appendix.
After matching, continuous variables following a
normal distribution were compared using the
paired-sample Student t test; otherwise, the Wil-
coxon rank sum test was used. Differences for
matched categorical variables were analyzed with
McNemar’s test. For the VARC-2 major endpoints
and other complications, frequencies and relative
numbers were given including the odds ratio (OR)
with 95% conﬁdence intervals (CIs) and p values of
FIGURE 1 Study Flow Chart
Bicuspid AS patients underwent TAVR
from 33 centers
(n = 576)
Bicuspid AS patients underwent TAVR
(n = 561)
Exclusion
• 15 patients with missing
   data
Exclusion
• 1330 patients with missing
   data
• 24 patients with degenerated
   bioprostheses
Bicuspid AS patients after PS matching
(n = 546)
Tricuspid AS patients after PS matching
(n = 546)
Tricuspid AS patients underwent TAVR
from 12 centers
(n = 5900)
Tricuspid AS patients underwent TAVR
(n = 4546)
PS matching
A total of 576 patients with bicuspid AS consecutively treated with TAVR were enrolled from 33 centers. For the purpose of this study, data
from 4,546 patients with tricuspid AS consecutively undergoing TAVR were collected from 12 participating centers. After propensity
score matching, 546 patients with bicuspid and tricuspid AS were compared. AS ¼ aortic valve stenosis; PS ¼ propensity score;
TAVR ¼ transcatheter aortic valve replacement.
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McNemar’s test for the propensity score–matched
cohorts or the chi-square test for the subgroup
analysis. Cumulative survival rates were analyzed
using the Kaplan-Meier method, and were compared
using win ratio tests for the propensity score–
matched cohort and log-rank test for the subgroup
analysis (24). All statistical analyses were performed
using SPSS software version 21.0 (SPSS, Inc., Chi-
cago, Illinois) and R software version 2.12.2 (25). A 2-
sided p value <0.05 was considered to indicate
statistical signiﬁcance.
RESULTS
BASELINE CHARACTERISTICS. A total of 576
patients with bicuspid AS were treated with TAVR
across 33 participating centers between April 2005
and May 2016. During the same period, a total of
5,900 patients with tricuspid AS were treated with
TAVR across 12 participating centers. Patients with
missing data or those who received TAVR for degen-
erated bioprostheses were excluded from the anal-
ysis. Consequently, 561 patients with bicuspid AS and
4,546 patients with tricuspid AS were included in the
present analysis (Figure 1). The type of bicuspid AS
was diagnosed in 497 patients (88.6%): type 0 was
diagnosed in 63 patients (12.7%), type 1 in 426
(85.7%), and type 2 in 8 (1.6%).
In the unadjusted cohort, patients with bicuspid
AS were younger and more likely to be male,
whereas patients with tricuspid AS were more likely
to have multiple comorbidities (Online Table 1). In
terms of surgical risk, patients with bicuspid AS had
a lower Logistic European System for Cardiac Oper-
ative Risk Evaluation (EuroSCORE) (14.8  12.3% vs.
16.7  11.8%; p ¼ 0.003) and Society of Thoracic
Surgeons (STS) score (5.0  5.1% vs. 6.5  8.8%;
p < 0.001). Furthermore, large prostheses were used
more often in the bicuspid AS group (34.5% vs.
14.5%; p < 0.001), whereas the transfemoral
approach was equally frequent in both groups. After
performing propensity score matching, both groups
were well matched, with no signiﬁcant differences in
baseline characteristics, except more frequent use of
the largest prostheses in the bicuspid AS group
(Table 1).
PROCEDURAL AND CLINICAL OUTCOMES. Table 2
summarizes the procedural and clinical outcomes of
the propensity score–matched cohort. Compared with
patients with tricuspid AS, patients with bicuspid AS
had more frequent conversion to surgery, implanta-
tion of second valve, and moderate or severe
paravalvular leak, as well as a lower device success
rate. There was no signiﬁcant difference in new
permanent pacemaker insertion between the bicuspid
and tricuspid AS groups.
In terms of 30-day clinical outcomes, there
were no signiﬁcant differences between the bicuspid
TABLE 1 Baseline Characteristics
Propensity Score Matched Cohort
Bicuspid AS
(n ¼ 546)
Tricuspid AS
(n ¼ 546) p Value
Age, yrs 77.2  8.2 77.2  8.8 0.91
Male 343 (62.8) 331 (60.6) 0.48
NYHA functional
class III or IV
439 (80.4) 428 (82.1) 0.48
Logistic EuroSCORE, % 16.1  12.0 16.9  13.9 0.58
STS score, % 4.6  4.6 4.3  3.0 0.29
Hypertension 382 (70.0) 385 (70.5) 0.89
Diabetes mellitus 128 (23.4) 127 (23.3) >0.99
Creatinine, mg/dl 1.2  0.9 1.2  0.7 0.81
Peripheral vascular
disease
83 (15.2) 85 (15.6) 0.93
Prior cerebrovascular
accident
77 (14.1) 69 (12.6) 0.53
Chronic lung disease 98 (17.9) 82 (15.0) 0.23
Prior PCI 121 (22.2) 128 (23.4) 0.66
Prior CABG 62 (11.4) 67 (12.3) 0.70
Echocardiographic ﬁndings
Mean gradient, mm Hg 49.7  17.7 48.5  17.1 0.25
Aortic valve area, cm2 0.7  0.2 0.7  0.2 0.86
LVEF, % 51.6  15.0 51.6  15.2 0.99
Procedural data
Transfemoral access 432 (85.9) 430 (86.2) 0.93
Device
Early-generation
devices
320 (58.6) 321 (58.8) >0.99
Sapien XT 155 (28.4) 150 (27.5) 0.77
CoreValve 165 (30.2) 171 (31.3) 0.73
New-generation
devices
226 (41.4) 225 (41.2) >0.99
Sapien 3 160 (29.3) 162 (29.7) 0.94
Lotus 43 (7.9) 47 (8.6) 0.73
Evolut R 23 (4.2) 16 (2.9) 0.32
Size*
Small 105/503 (20.9) 152/499 (30.5) 0.001
Medium 226/503 (44.9) 238/499 (47.7) 0.38
Large 172/503 (34.2) 109/499 (21.8) <0.001
Type of bicuspid
Determined 478 (87.5) —
Type 0 61 (12.8) —
Type 1 409 (85.6) —
Type 2 8 (1.7) —
Undetermined/
unavailable
68 (12.5) —
Values are mean  SD, n (%), or n/N (%). *Small ¼ 23 mm for Sapien XT/Sapien 3
and #26 mm for CoreValve/Evolut R; medium ¼ 26 mm for Sapien XT/Sapien 3
and 29 mm for CoreValve/Evolut R; large ¼ 29 mm for Sapien XT/Sapien 3, 31 mm
for CoreValve, and 34 mm for Evolut R.
AS ¼ aortic valve stenosis; CABG ¼ coronary artery bypass graft; EuroSCORE ¼
European System for Cardiac Operative Risk Evaluation; LVEF ¼ left ventricular
ejection fraction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous
coronary intervention; STS ¼ Society of Thoracic Surgeons.
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and tricuspid AS groups in 30-day all-cause
mortality, stroke, life-threatening bleeding, major
vascular complications, and stage 2 or 3 acute kidney
injury.
Outcomes accord ing to dev ice type . When strati-
ﬁed according to whether they received early- versus
new-generation devices, patients with bicuspid AS
had more frequent procedural complications than
those with tricuspid AS when receiving the early-
generation devices (conversion to surgery: 2.5% vs.
0.3%; p ¼ 0.02; second valve implantation: 7.2% vs.
2.2%; p ¼ 0.003; moderate or severe paravalvular
leak: 15.9% vs. 10.3%; p ¼ 0.03) (Figure 2A). However,
there were no signiﬁcant differences in procedural
complications between the bicuspid and tricuspid AS
groups when receiving the new-generation devices
(Figure 2B). These ﬁndings were consistently
observed in propensity score matched cohorts for
early- and new-generation devices (Online Figure 1).
Procedural and clinical outcomes according to
device type are shown in Online Figure 2. Compared
with patients with tricuspid AS, patients with
bicuspid AS had more frequent aortic root injury
(4.5% vs. 0.0%; p ¼ 0.015) when receiving the Sapien
XT. In addition, patients with bicuspid AS had more
frequent second valve implantation (11.6% vs. 2.9%;
p ¼ 0.002), moderate or severe paravalvular leak
(19.4% vs. 10.5%; p ¼ 0.02), and subsequent lower
device success rate (72.1% vs. 86.0%; p ¼ 0.002) than
those with tricuspid AS when receiving the
CoreValve. However, there were no signiﬁcant dif-
ferences in these adverse procedural events between
groups when receiving the Sapien 3 and Lotus.
There were no signiﬁcant differences in 30-day
mortality and other major clinical endpoints
between groups, except that patients with bicuspid
AS had a higher rate of major vascular complications
compared with patients with tricuspid AS when
receiving the Sapien XT (5.8% vs. 0.7%; p ¼ 0.01)
(Online Figures 3 to 5).
In terms of outcomes across bicuspid phenotype,
there were no signiﬁcant differences in procedural
and clinical outcomes between type 0 and type 1
bicuspid AS (Online Table 2). Of note, moderate or
severe paravalvular leak occurred in 5 patients
(8.2%) for type 0 bicuspid AS and 44 patients
(10.8%) for type 1 bicuspid AS (p ¼ 0.54), whereas all
aortic root injury occurred only in patients with type
1 bicuspid AS.
Midterm morta l i ty . Over a median follow-up period
of 460 days (IQR: 90 to 710 days), 66 patients died in
the bicuspid AS group and 73 patients died in the
tricuspid AS group. There were no differences be-
tween the 2 groups in cumulative event rates for all-
cause mortality at the 2-year follow-up (17.2% vs.
19.4%; p ¼ 0.28) (Central Illustration). Furthermore,
there were no signiﬁcant differences in 1-year all-
cause mortality rates between groups with stratiﬁca-
tion according to early- and new-generation devices
(early-generation devices: 14.5% vs. 13.7%; log-rank
p ¼ 0.80; new-generation devices: 4.5% vs. 7.4%;
log-rank p ¼ 0.64) (Figures 3A and 3B). These ﬁndings
were consistently observed in propensity score–
matched cohorts for early- and new-generation de-
vices (Online Figures 6A and 6B).
DISCUSSION
The present study is the ﬁrst large-scale study to
compare the safety, efﬁcacy, and clinical outcomes of
TAVR in patients with bicuspid and tricuspid AS. The
major ﬁndings of the present study are as follows:
1. In the propensity score–matched cohort, TAVR in
patients with bicuspid AS was associated with
more frequent adverse procedural events
compared with those with tricuspid AS. These dif-
ferences were observed among patients treated
with the early-generation devices.
TABLE 2 Procedural and Clinical Outcomes
Propensity Score Matched Cohort
Bicuspid AS
(n ¼ 546)
Tricuspid AS
(n ¼ 546) p Value OR (95% CI)
Procedural outcomes
Procedure-related death 7 (1.3) 6 (1.1) >0.99 1.17 (0.39–3.47)
Conversion to surgery 11 (2.0) 1 (0.2) 0.006 11.00 (1.42–85.20)
Coronary obstruction 5 (0.9) 3 (0.5) 0.73 1.67 (0.40–6.97)
Aortic root injury 9 (1.6) 0 (0.0) 0.004 —
Implantation of 2 valves 26 (4.8) 8 (1.5) 0.002 3.71 (1.61–8.56)
New permanent pacemaker 84 (15.4) 84 (15.4) >0.99 1.00 (0.72–1.39)
Echocardiographic ﬁndings
Mean gradient, mm Hg 10.8  6.7 10.2  4.4 0.18
LVEF, % 54.2  13.6 54.7  13.9 0.79
Moderate or severe
paravalvular leak
57 (10.4) 37 (6.8) 0.04 1.61 (1.04–2.48)
Device success 466 (85.3) 499 (91.4) 0.002 0.54 (0.37–0.80)
30-day outcomes
All-cause mortality 20 (3.7) 18 (3.3) 0.87 1.11 (0.59–2.10)
Stroke 16 (2.9) 10 (1.8) 0.33 1.60 (0.73–3.53)
Nondisabling 7 (1.3) 6 (1.1) >0.99 1.17 (0.39–3.47)
Disabling 9 (1.6) 4 (0.7) 0.27 2.25 (0.69–7.31)
Bleeding
Major 20 (3.7) 22 (4.0) 0.88 0.91 (0.50–1.67)
Life-threatening 11 (2.0) 19 (3.5) 0.20 0.58 (0.28–1.22)
Major vascular complication 16 (2.9) 16 (2.9) >0.99 1.00 (0.50–2.00)
Acute kidney injury
(stage 2 or 3)
11 (2.0) 5 (0.9) 0.21 2.20 (0.77–6.33)
Values are n (%) or mean  SD, unless otherwise indicated.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
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2. However, there were no signiﬁcant differences in
procedural complications between groups when
using the new-generation devices.
3. The cumulative event rates for all-cause mortality
at 2-year follow-up were comparable between the
bicuspid and tricuspid groups.
Recently, 2 multicenter studies demonstrated the
acceptable clinical outcomes of TAVR for bicuspid AS
(8,10). However, patients included in those studies
were younger and had less comorbidities compared
with most published trials and observational studies
including patients with tricuspid AS. Given that
patients with bicuspid AS have less coexisting
comorbidities compared with patients with tricuspid
AS, there is a potential risk that clinical outcomes of
TAVR for bicuspid AS could differ from those for
tricuspid AS with equivalent surgical risk. In the
present study, patients with bicuspid AS in the crude
cohort were younger and had less comorbidity than
those with tricuspid AS. Both the bicuspid and
tricuspid AS groups had an intermediate-risk proﬁle,
with mean logistic EuroSCOREs of 14.8% and 16.7%,
and mean STS scores of 5.0% and 6.5%, respectively.
In the present study, compared with tricuspid AS,
TAVR in bicuspid AS was associated with similar
FIGURE 2 Procedural Outcomes in Bicuspid and Tricuspid AS With Early- and New-Generation Devices
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prognosis, although the device success was lower.
The accumulation of a large multicenter database has,
for the ﬁrst time, allowed comparisons of matched
cohorts, as well as the potential effect of differences
in device type.
The present study also showed that procedural
challenges of TAVR in bicuspid AS and related
outcomes differed according to early- and
new-generation devices. Within the group receiving
the early-generation devices, patients with bicuspid
CENTRAL ILLUSTRATION TAVR for Bicuspid Versus Tricuspid Aortic Valve Stenosis
Yoon, S.-H. et al. J Am Coll Cardiol. 2017;69(21):2579–89.
(Top) Schematic presentations of bicuspid and tricuspid aortic valves. Type 0 and 1 indicate bicuspid aortic valve with no raphe, and 1 raphe, respectively. (Bottom)
Cumulative all-cause mortality rates in patients with bicuspid AS (orange) and tricuspid AS (blue) in a propensity score matched cohort. Event rates were compared
using the win ratio test. AS ¼ aortic valve stenosis.
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AS had more frequent aortic root injury, mainly
related to Sapien XT implantation, and second valve
implantation and moderate or severe paravalvular
leak, mainly related to CoreValve implantation.
Among those treated with the new-generation de-
vices, however, there were no signiﬁcant differences
in procedural outcomes between the bicuspid and
tricuspid groups. The new-generation devices were
FIGURE 3 Kaplan-Meier Curves for All-Cause Mortality According to Early- and New-Generation Devices
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generation devices, respectively. Event rates were compared using the log-rank test.
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developed to mitigate the critical limitations of the
early-generation devices: signiﬁcant paravalvular
leak, difﬁculty with optimal positioning, and vascular
complications. All of these adverse events were re-
ported to be associated with worse outcomes (26–29).
The new-generation balloon-expandable Sapien 3,
with an external sealing cuff allowing for effective
sealing, eliminates the extreme oversizing and miti-
gates the morphological challenges of bicuspid AS.
Similarly, the mechanical expanding Lotus valve,
with an outer adaptive seal, as well as retrievability
and repositioning capacity, may ameliorate the difﬁ-
culties in optimal positioning and prevent para-
valvular leak. The present study showed that the
initial attempt of device advancement succeeded in
overcoming the procedural limitations in tricuspid
AS, and now goes beyond the challenges of treating
bicuspid AS.
Given that a recent randomized trial demonstrated
similar survival rates between TAVR and surgery in
intermediate-risk patients (6), the extension of TAVR
may be considered for younger and lower-risk pa-
tients with a possibly increased proportion of
bicuspid AS. Despite procedural challenges of TAVR
in bicuspid AS, the present study showed similar
overall mortality rates between the bicuspid and
tricuspid AS groups. This suggests that long-term
mortality of patients with bicuspid AS is determined
by multiple factors that also affect the prognosis of
the tricuspid AS population.
Several essential factors should be considered in
treating patients with bicuspid AS. Sievers et al. (30)
showed a similar late survival and freedom from
reoperation after surgery between the different types
of bicuspid aortic valves. However, given the nature
of transcatheter heart valves, future studies should
evaluate the association between the types of
bicuspid aortic valves and outcomes after TAVR.
Furthermore, management of concomitant aortop-
athy in treating patients with bicuspid aortic valve
should be taken into account. The risk of aortic
rupture or dissection is greater in patients with a
bicuspid aortic valve than in the general population
(31), and also increases owing to aging-related pro-
gressive aortic dilation and degeneration (32). Given
the expanding indication of TAVR for younger and
lower-risk patients, physicians will face this dilemma
in treating relatively younger patients with bicuspid
AS and concomitant aortopathy. Several factors,
including age, comorbidities, and additional risk
factors for aortic complications, must be considered
during the decision-making process to treat patients
with bicuspid aortic valve and concomitant aortop-
athy (33). Nevertheless, longer life expectancy in
those patient populations mandates future studies to
evaluate the effect of concomitant aortopathy, as well
as valve durability for long-term follow-up.
STUDY LIMITATIONS. First, this study had the
inherent limitations of an observational study
without center-independent adjunction of adverse
events and an independent core laboratory to
diagnose bicuspid AS and assess paravalvular leak.
Moreover, although propensity score matching is a
well-accepted approach in observational research to
address differences in baseline characteristics, it
cannot account for unmeasured bias. Last, device se-
lection was not randomized, but was at the operator’s
discretion, and patient selection as well as operator
experience may have affected the observed outcomes.
CONCLUSIONS
Compared with tricuspid AS, TAVR in bicuspid AS was
associated with a similar prognosis, but a lower
device success rate. Procedural differences were
observed in patients treated with the early-
generation devices, whereas no differences were
observed with the new-generation devices.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Compared with those with
tricuspid AS, patients with bicuspid valves undergoing
TAVR with early-generation devices more often
developed adverse procedural events, but there were
no signiﬁcant differences between groups in
procedural complications with newer-generation
devices. Cumulative all-cause mortality at 2-year
follow-up was comparable between the bicuspid and
tricuspid groups.
TRANSLATIONAL OUTLOOK: Larger studies are
needed to evaluate the long-term outcomes and
durability of TAVR in patients with bicuspid AS.
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